一名17岁的男性青少年患有耐火性克朗氏病,用乌帕达西替尼和瑞桑基祖马布联合疗法治疗:病例报告和对当前证据的审查
Mohammad Alhashemi1, Mohammad Shehab1
1Haya Al-Habib Gastroenterology Center, Mubarak Al-Kabeer Hospital, Jabriya, Kuwait.
The American journal of case reports
|January 16, 2026
概括
这项案例研究表明,将上达西提尼布和瑞桑基祖马布结合起来,有效地治疗了患有严重克罗恩氏病的年轻患者.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 克罗恩氏病 (CD) 是一种影响肠道的自身免疫性疾病.
- 中度至重度的CD需要先进的疗法,如生物药物和小分子.
- 乌帕达西提尼布 (JAK1抑制剂) 和瑞桑基祖马布 (IL-23抑制剂) 对耐火性CD显示出有前途.
研究的目的:
- 报告一个青少年患有耐火克罗恩病的病例.
- 为了评估联合上达西提尼布和瑞桑基祖马布治疗的疗效.
- 为突出针对治疗耐药性炎症性肠病的先进向治疗.
主要方法:
- 一名17岁的男性有7年的CD病史接受了治疗.
- 该患者之前的多种疗法都失败了,包括infliximab,adalimumab,ustekinumab,以及用upadacitinib单独治疗.
- 结合疗法包括口服的阿帕达西提尼布和静脉/皮肤下注射的瑞桑基祖马布.
主要成果:
- 患者获得了完全的临床和生化缓解.
- 9个月内镜评估显示静止疾病 (克罗恩病简单内镜评分<4).
- 在联合治疗后,便中calprotectin水平正常化.
结论:
- 结合上达西替尼和瑞桑基祖马布治疗对耐火性克罗恩病有效.
- 这种方案支持最近关于炎症性肠病先进向治疗的研究结果.
- 这种组合为治疗耐药性CD患者提供了可行的二线治疗选择.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
721
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
721
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
780
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
780
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
897
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
897
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
703
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
703
Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K
Inflammatory Bowel Disease III: Crohn's Disease
69
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
69


